^
Association details:
| Biomarker: | BIRC5 expression |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination therapy with DPX-Survivac, intermittent low-dose cyclophosphamide (CPA) and pembrolizumab for the treatment of advanced and metastatic solid tumors: Early safety and efficacy results from a phase II basket study.
Published date:
05/28/2020
Excerpt:
Subjects with survivin-expressing advanced, recurrent HCC, NSCLC, bladder and MSI-H tumors are enrolled to single arm…DPXSurvivac/CPA with pembrolizumab is well tolerated and shows early signs of clinical efficacy and disease control in advanced and metastatic solid tumors...
Secondary therapy:
cyclophosphamide + MVP-S
Trial ID:
